Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.

Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, Woods M, Fu B, Yang F, Chen E, Ostermaier M, Stankovic T, Ponstingl H, Herzog M, Yusa K, Martinez FM, Durant ST, Galanty Y, Beli P, Adams DJ, Bradley A, Metzakopian E, Forment JV, Jackson SP.

Nat Commun. 2019 Jan 8;10(1):87. doi: 10.1038/s41467-018-07729-2.

2.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.

Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnström P, Varnäs K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M.

Sci Adv. 2018 Jun 20;4(6):eaat1719. doi: 10.1126/sciadv.aat1719. eCollection 2018 Jun.

3.

Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.

Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K.

Mol Cancer Ther. 2018 Aug;17(8):1637-1647. doi: 10.1158/1535-7163.MCT-17-0975. Epub 2018 May 16.

PMID:
29769307
4.

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).

Pike KG, Barlaam B, Cadogan E, Campbell A, Chen Y, Colclough N, Davies NL, de-Almeida C, Degorce SL, Didelot M, Dishington A, Ducray R, Durant ST, Hassall LA, Holmes J, Hughes GD, MacFaul PA, Mulholland KR, McGuire TM, Ouvry G, Pass M, Robb G, Stratton N, Wang Z, Wilson J, Zhai B, Zhao K, Al-Huniti N.

J Med Chem. 2018 May 10;61(9):3823-3841. doi: 10.1021/acs.jmedchem.7b01896. Epub 2018 May 2.

PMID:
29683659
5.

Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.

Ward TA, McHugh PJ, Durant ST.

PLoS One. 2017 Jun 19;12(6):e0179278. doi: 10.1371/journal.pone.0179278. eCollection 2017.

6.

Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site.

Exell JC, Thompson MJ, Finger LD, Shaw SJ, Debreczeni J, Ward TA, McWhirter C, Siöberg CL, Martinez Molina D, Abbott WM, Jones CD, Nissink JW, Durant ST, Grasby JA.

Nat Chem Biol. 2016 Oct;12(10):815-21. doi: 10.1038/nchembio.2148. Epub 2016 Aug 15.

7.

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.

Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, Hayes JD.

Free Radic Biol Med. 2015 Nov;88(Pt B):108-146. doi: 10.1016/j.freeradbiomed.2015.06.021. Epub 2015 Jun 27. Review.

8.

Development of a high-throughput fluorescence polarization DNA cleavage assay for the identification of FEN1 inhibitors.

McWhirter C, Tonge M, Plant H, Hardern I, Nissink W, Durant ST.

J Biomol Screen. 2013 Jun;18(5):567-75. doi: 10.1177/1087057113476551. Epub 2013 Feb 20.

PMID:
23427045
9.

Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives.

Tucker JA, Bennett N, Brassington C, Durant ST, Hassall G, Holdgate G, McAlister M, Nissink JW, Truman C, Watson M.

PLoS One. 2012;7(12):e50889. doi: 10.1371/journal.pone.0050889. Epub 2012 Dec 10.

10.

Telomerase-independent paths to immortality in predictable cancer subtypes.

Durant ST.

J Cancer. 2012;3:67-82. doi: 10.7150/jca.3965. Epub 2012 Jan 31.

11.

Metnase promotes restart and repair of stalled and collapsed replication forks.

De Haro LP, Wray J, Williamson EA, Durant ST, Corwin L, Gentry AC, Osheroff N, Lee SH, Hromas R, Nickoloff JA.

Nucleic Acids Res. 2010 Sep;38(17):5681-91. doi: 10.1093/nar/gkq339. Epub 2010 May 10.

12.

DNA-PKcs and ATM co-regulate DNA double-strand break repair.

Shrivastav M, Miller CA, De Haro LP, Durant ST, Chen BP, Chen DJ, Nickoloff JA.

DNA Repair (Amst). 2009 Aug 6;8(8):920-9. doi: 10.1016/j.dnarep.2009.05.006. Epub 2009 Jun 16.

13.

p53 methylation--the Arg-ument is clear.

Durant ST, Cho EC, La Thangue NB.

Cell Cycle. 2009 Mar 15;8(6):801-2. Epub 2009 Mar 14.

PMID:
19221494
14.

Arginine methylation regulates the p53 response.

Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B, La Thangue NB.

Nat Cell Biol. 2008 Dec;10(12):1431-9. doi: 10.1038/ncb1802. Epub 2008 Nov 16.

PMID:
19011621
15.

UV radiation induces delayed hyperrecombination associated with hypermutation in human cells.

Durant ST, Paffett KS, Shrivastav M, Timmins GS, Morgan WF, Nickoloff JA.

Mol Cell Biol. 2006 Aug;26(16):6047-55.

16.

The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair.

Lee SH, Oshige M, Durant ST, Rasila KK, Williamson EA, Ramsey H, Kwan L, Nickoloff JA, Hromas R.

Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18075-80. Epub 2005 Dec 6.

17.

Good timing in the cell cycle for precise DNA repair by BRCA1.

Durant ST, Nickoloff JA.

Cell Cycle. 2005 Sep;4(9):1216-22. Epub 2005 Sep 13. Review.

PMID:
16103751
18.

Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX.

Mac Partlin M, Homer E, Robinson H, McCormick CJ, Crouch DH, Durant ST, Matheson EC, Hall AG, Gillespie DA, Brown R.

Oncogene. 2003 Feb 13;22(6):819-25.

PMID:
12584560
19.

Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes.

Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, Borts RH, Brown R.

Curr Biol. 1999 Jan 14;9(1):51-4.

Supplemental Content

Loading ...
Support Center